Nonsteroidal anti-inflammatory drugs (NSAIDs) seemed to neutralize the protective benefit of a certain bisphosphonate, according to a post-hoc analysis of a randomized controlled trial. Among over ...
Please provide your email address to receive an email when new articles are posted on . In a cohort of women, NSAID use significantly decreased the efficacy of the bisphosphonate clodronate for ...
Eleven trials with 754 participants, assessing alendronate, clodronate, neridronate, pamidronate, and zoledronate, were included. HealthDay News — Bisphosphonates may reduce complex regional pain ...
SAN ANTONIO — A recently presented study revealed that the bisphosphonate clodronate had a low incidence of adverse events and toxicity among patients with breast cancer and may modestly reduce the ...
PURPOSE: The development of bone metastases depends on tumor-induced osteoclastic resorption of bone, which may be inhibited by the antiosteolytic bisphosphonate clodronate. Given to patients with ...
One type of bisphosphonates, clodronate disodium, was chosen as the bisphosphonate for this study because of its popularity and ease of administration. It, along with others, are not approved for use ...
Simon et al reviewed the skeletal consequences of discontinuing HT and the specific treatment options for these women. [12] This analysis included 11 RCTs that reported data on BMD changes during and ...
hip fracture Researchers investigated whether hip fractures could be prevented with bisphosphonates in people with osteoporosis or osteopenia. A systematic review and meta-analysis found zoledronic ...
Mechanisms and Management of Toxicities Associated With High-Dose Interferon Alfa-2b Therapy PURPOSE: To determine clinical practice guidelines for the use of bisphosphonates in the prevention and ...
Santa Anita Park stewards disqualified Flagstaff from a runner-up finish in the Sept. 27 Santa Anita Sprint Championship Stakes (G2) after test results showed clodronate, a bisphosphonate, in his ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results